Axogen Raises 2026 Revenue Guidance Amid Product Expansion and Increased Payer Coverage

Axogen (AXGN) has raised its full-year 2026 revenue guidance to a minimum of $290 million following strong third-quarter performance. The company reported a 26.2% year-over-year revenue increase in Q3, driven by expanding surgical demand and significant growth in the breast reconstruction market, which saw over 60% growth. Strategic growth is being fueled by the acquisition of BioCircuit, introducing the NerveTape sutureless device to capture the direct nerve repair market. Additionally, Axogen has achieved a major milestone with commercial payer coverage for its Avance Nerve Graft reaching approximately 96% of covered U.S. lives. Looking forward, the company is preparing for a 2027 market launch in prostate nerve reconstruction, aiming to establish a new standard of care.

By The Motley Fool Team · Motley Fool ·

Axogen Raises 2026 Revenue Guidance Amid Product Expansion and Increased Payer Coverage

Tickers: $AXGN

Topics: Acquisition Healthcare Reimbursement Medical Devices Revenue Guidance

Read the full article at Motley Fool

More World news